Technology platform

A unique and flexible platform with broad applicability
Patient case (#2)

A unique and flexible platform with broad applicability

PRECIRIX’ platform allows the design and development of novel radiopharmaceuticals or targeted radioligand therapies, a technology in which radionuclides are attached to ligands that direct them to their specific target on the cancer cell. The radioactive payload is delivered in a highly selective manner to the tumor, limiting radiation to the rest of the body.

Our technology platform facilitates development of sdAbs for multiple targets, in combination with different isotopes and applicability in various settings.

A Unique platform

Single-domain antibody targets the cancer

On target in minutes after IV infusion anywhere in the body. Deep tumor penetration and prolonged tumor retention. Rapid renal clearance of unbound product.

Radioisotope kills through DNA breaks

Direct cell killing and bystander effects.

A Flexible platform

Multiple targets

Cancer cells
Specific epitopes
Tumor microenvironment

Different isotopes

Alpha emitters
Beta emitters

Various applications

Patient selection
Combination therapy


CAM-H2, consists of an HER2-targeting single-domain antibody linked to iodine-131. This targeted radioligand therapy is being developed for the treatment of patients with metastatic HER2-positive cancer indications, such as breast and gastric adenocarcinoma.

CAM-FAP, a single-domain antibody construct targeting fibroblast activation protein alpha is nearing IND readiness.

In addition to the lead program, the company has two compounds in advanced preclinical stage, targeting fibroblast activation protein and folate receptor alpha.

PRECIRIX’ research program further focuses on the evaluation of different linkers, isotopes and new sdAbs.

Pre-clinical Phase Ⅰ Phase Ⅰ/Ⅱ Phase Ⅲ Market
CAM-H2 HER2+ Metastatic Cancer
CAM-FAP FAP+ cancer
Early programs Platform
  • Completed
  • Ongoing

Clinical trial

A unique and flexible platform with broad applicability
Keyaerts et al. UZ Brussel, VUB

The company is conducting a Phase I/II study to evaluate CAM-H2 treatment in patients with advanced / metastatic HER2-positive breast and gastroesophageal cancer.

Research demonstrated the specific uptake of CAM-H2 in brain lesions of patients with brain metastases from HER2-positive breast carcinoma. Therefore, the phase I/II trail will evaluate the impact of CAM-H2 on brain metastases, which are frequently observed in metastatic breast cancer.

The dose-escalation phase of the trial has been finalized, demonstrating safety and specific targeting of cancer cells.


Your browser is not supported. Update your browser for more security, speed and to make the most of this site.